IL-7 was found to promote resistance to GC therapy in patients with T cell-acute lymphoblastic leukemia, suggesting that this disease could be treated by inhibiting the IL-7R/JAK/STAT5 pathway. This evidence concerns the gene STAT5B and acute lymphoblastic leukemia.